Sign In
Get Started →
Rachel W. Humphrey, MD
Independent Board Director at Xilio Therapeutics, Inc.
Summary
Rachel W. Humphrey, MD is a seasoned pharmaceutical executive with over 18 years of experience in Product Development, specializing in small molecules, cytotoxics, and biologics in the fields of oncology and immuno-oncology. With a track record of successfully managing the development of 2 new molecular entities, NEXAVAR and YERVOY, she has held significant leadership roles in top pharmaceutical companies and small biotechs. Rachel's expertise extends to supervising Product Development strategies from pre-IND to Phase IV and compound commercialization.
This public profile is provided courtesy of Clay. All information found here is in the public domain.
This public profile is provided courtesy of Clay. All information found here is in the public domain.